BC Innovations | Jan 12, 2018
Translation in Brief

In the twenties

A Cancer Cell study from University of Southampton and Celldex Therapeutics Inc. (NASDAQ:CLDX) researchers suggests combining CD27 agonists with tumor-targeting mAbs could help myeloid cells attack a broad array of cancers. The partners are testing...
BC Week In Review | May 19, 2014
Company News

Celldex, Bristol-Myers deal

Celldex partnered with Bristol-Myers Squibb in an exclusive deal to evaluate combinations of anti- PD-1 receptor ( PDCD1 ; PD-1; CD279 ) antagonist antibodies with anti- CD27 agonist antibodies. Under the deal, Celldex will run a Phase...
BC Extra | May 15, 2014
Top Story

BMS, Celldex to study nivolumab, CDX-1127

Celldex Therapeutics Inc. (NASDAQ:CLDX) jumped $3.34 (27%) to $15.74 on Wednesday after announcing an exclusive deal with Bristol-Myers Squibb Co. (NYSE:BMY) to evaluate combinations of anti- PD-1 receptor ( PDCD1 ; PD-1; CD279 ) antagonist antibodies with...
Items per page:
1 - 3 of 3